PURE Bioscience (OTCMKTS:PURE – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.01) EPS for the quarter, Zacks reports. The business had revenue of $0.51 million for the quarter.
PURE Bioscience Trading Down 12.1%
Shares of OTCMKTS:PURE opened at $0.06 on Wednesday. PURE Bioscience has a 52 week low of $0.04 and a 52 week high of $0.14. The company’s 50 day moving average is $0.07 and its two-hundred day moving average is $0.06. The company has a market cap of $8.00 million, a PE ratio of -2.05 and a beta of 0.16.
About PURE Bioscience
PURE Bioscience, Inc is a San Diego, California–based company that develops and markets patented antimicrobial solutions for diverse industries. At the core of its technology portfolio is Silver Dihydrogen Citrate (SDC), an EPA-registered broad-spectrum biocide designed to neutralize bacteria, viruses, and fungi on contact. The company targets applications in food processing, water treatment, personal care, and medical device sanitation.
PURE’s product suite includes concentrate formulations and ready-to-use solutions.
Read More
- Five stocks we like better than PURE Bioscience
- Could a Tesla-SpaceX Merger Be Closer Than Investors Think?
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
